CR10345A - Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion - Google Patents

Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion

Info

Publication number
CR10345A
CR10345A CR10345A CR10345A CR10345A CR 10345 A CR10345 A CR 10345A CR 10345 A CR10345 A CR 10345A CR 10345 A CR10345 A CR 10345A CR 10345 A CR10345 A CR 10345A
Authority
CR
Costa Rica
Prior art keywords
methods
derivatives
embryous
compositions
include human
Prior art date
Application number
CR10345A
Other languages
English (en)
Inventor
Geeta Shroff
Original Assignee
Geeta Shroff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geeta Shroff filed Critical Geeta Shroff
Publication of CR10345A publication Critical patent/CR10345A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/31—Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica que comprende preparaciones de celulas madre embrionarias humanas (hes) y sus derivados; y a metodos para su transplante en el cuerpo humano, en donde el transplante da como resultado la inversion clinica de sintomas; cura, estabilizacion o detencion de degeneracion de una amplia variedad de condiciones, enfermedades y trastornos medicos actualmente incurables y terminales.
CR10345A 2006-03-07 2008-10-06 Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion CR10345A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN582DE2006 2006-03-07
IN1500DE2006 2006-06-26
US84435006P 2006-09-14 2006-09-14

Publications (1)

Publication Number Publication Date
CR10345A true CR10345A (es) 2009-03-30

Family

ID=54150153

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10345A CR10345A (es) 2006-03-07 2008-10-06 Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion

Country Status (23)

Country Link
US (9) US10545135B2 (es)
EP (11) EP2422794A3 (es)
JP (2) JP5649786B2 (es)
KR (2) KR101505382B1 (es)
CN (2) CN103893211A (es)
AP (1) AP2949A (es)
AU (1) AU2007257594B2 (es)
BR (1) BRPI0708576A2 (es)
CA (1) CA2644922C (es)
CR (1) CR10345A (es)
CU (1) CU20080161A7 (es)
DK (1) DK1993575T3 (es)
EA (1) EA027648B9 (es)
EC (1) ECSP088799A (es)
GE (1) GEP20135796B (es)
IL (1) IL193702A (es)
MA (1) MA30323B1 (es)
MX (1) MX347303B (es)
MY (1) MY154677A (es)
NO (1) NO20084181L (es)
NZ (2) NZ594639A (es)
PH (1) PH12014501028A1 (es)
WO (1) WO2007141657A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2422794A3 (en) 2006-03-07 2013-03-13 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
WO2008132722A1 (en) 2007-04-26 2008-11-06 Ramot At Tel-Aviv University Ltd. Pluripotent autologous stem cells from oral mucosa and methods of use
JP5567476B2 (ja) * 2007-05-28 2014-08-06 モナッシュ ユニバーシティ 慢性肺疾患の治療
US20090291061A1 (en) * 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
US10456425B2 (en) * 2008-06-11 2019-10-29 Fresenius Medical Care Deutschland Gmbh Conditioned medium of liver progenitor cells
US20100010087A1 (en) * 2008-07-10 2010-01-14 Hong John J Methods for Inducing Stem Cell Migration and Specialization with EC-18
ES2932850T3 (es) * 2008-11-14 2023-01-27 Viacyte Inc Encapsulación de células pancreáticas derivadas de células madre pluripotentes humanas
US8377432B2 (en) * 2009-09-02 2013-02-19 Khay-Yong Saw Method and composition for neochondrogenesis
CA2772619C (en) * 2009-09-04 2019-07-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for enhancing genome stability and telomere elongation in embryonic stem cells
US20120201791A1 (en) * 2009-10-15 2012-08-09 Tai June Yoo Methods of treating diseases or conditions using mesenchymal stem cells
JP5035737B2 (ja) * 2009-12-07 2012-09-26 国立大学法人名古屋大学 脂肪組織由来間葉系幹細胞を含有する、前立腺癌治療用細胞製剤
WO2011127113A1 (en) * 2010-04-08 2011-10-13 Anthrogenesis Corporation Treatment of sarcoidosis using placental stem cells
WO2011145110A1 (en) 2010-05-15 2011-11-24 Subhadra Dravida A novel cord blood plasma nutrient formulation and a method for the preparation thereof
TWI607757B (zh) * 2010-11-10 2017-12-11 英瑞金公司 治療製劑
FR2986537B1 (fr) * 2012-02-07 2014-03-28 Oreal Procede d'evaluation d'actif(s) apte(s) a preserver la fonctionnalite des cellules souches epitheliales
US20150079047A1 (en) * 2012-04-16 2015-03-19 The Regents Of The University Of California Ocular therapeutics using embryonic stem cell microvesicles
WO2014089121A2 (en) * 2012-12-03 2014-06-12 Thomas Ichim Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
WO2014116786A1 (en) * 2013-01-25 2014-07-31 Zietchick Research Institute,Llc Use of human chorionic gonadotropin to treat cerebral palsy and/or its co-morbidities
CN103961373A (zh) 2013-02-04 2014-08-06 西比曼生物科技（上海）有限公司 异体间质血管层细胞和异体间充质祖细胞在预防或治疗骨性关节炎中的应用
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
ITMI20130513A1 (it) * 2013-04-05 2014-10-06 Euroclone S P A Metodo diagnostico per patologie autoimmuni del fegato
US10597633B2 (en) 2014-05-16 2020-03-24 Koninklijke Nederlandse Akademie Van Wetenschappen Culture method for organoids
KR101686315B1 (ko) 2015-01-09 2016-12-13 이화여자대학교 산학협력단 편도 유래 중간엽 줄기세포로부터 슈반 세포의 분화 방법
KR20160109358A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 면역 질환 예방 또는 치료용 조성물
KR20160109356A (ko) 2015-03-11 2016-09-21 이화여자대학교 산학협력단 자가 면역 질환 예방 또는 치료용 조성물
KR102036029B1 (ko) 2015-03-11 2019-10-24 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
US10870830B2 (en) 2015-03-26 2020-12-22 EWHA University—Industry Collaboration Foundation Method for culturing differentiation-promoting and -sustaining spheroid form of tonsil-derived stem cells
ES2910032T3 (es) 2015-06-01 2022-05-11 Memorial Sloan Kettering Cancer Center Métodos de diferenciación in vitro de neuronas dopaminérgicas del mesencéfalo (mDA)
EP3411048A4 (en) 2016-02-05 2019-07-31 Memorial Sloan-Kettering Cancer Center METHOD FOR THE DISTINCTION OF PRECURSORS OF STEM CELLS FROM THE ECOTODERMAL DESCALING LINE
CN105749254A (zh) * 2016-02-28 2016-07-13 深圳爱生再生医学科技有限公司 用于治疗血管性痴呆的干细胞制剂及其制备方法和应用
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
EP3464567A4 (en) 2016-05-27 2020-01-08 Memorial Sloan Kettering Cancer Center METHODS FOR DIFFERENTIATION OF STEM CELL-DERIVED PROPERTIES
US20180242590A1 (en) * 2016-09-23 2018-08-30 Peter Friedman Compositions and methods for treating citrus plants infected with bacteria and for promoting general agricultural health
CN106177918A (zh) * 2016-09-30 2016-12-07 广州赛莱拉干细胞科技股份有限公司 一种间充质干细胞注射液及其制备方法和应用
AU2018215170B2 (en) * 2017-01-31 2021-11-11 Osaka University Differentiation control method for pluripotent stem cells
WO2019040790A1 (en) 2017-08-23 2019-02-28 Merakris Therapeutics, Llc COMPOSITIONS CONTAINING AMNIOTIC COMPONENTS AND METHODS FOR THEIR PREPARATION AND USE
KR102130493B1 (ko) 2018-07-11 2020-07-06 이화여자대학교 산학협력단 건선 예방 또는 치료용 조성물
KR102089476B1 (ko) 2018-07-11 2020-03-16 이화여자대학교 산학협력단 피부 염증 질환 예방 또는 치료용 조성물
KR20190120141A (ko) 2019-10-16 2019-10-23 이화여자대학교 산학협력단 골수 부전 예방 또는 치료용 조성물
KR20210119766A (ko) * 2020-03-25 2021-10-06 서울대학교병원 인간 배아줄기세포 유래 중간엽 줄기세포를 포함하는 망막색소변성의 예방 또는 치료용 약학적 조성물
WO2022221765A1 (en) 2021-04-16 2022-10-20 Brainxell, Inc. Methods of making, expanding and purifying midbrain dopaminergic progenitor cells
CN113116933A (zh) * 2021-04-26 2021-07-16 河北医科大学第四医院 一种防治糖尿病足的干细胞组合物及其应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744347A (en) 1987-01-16 1998-04-28 Ohio University Edison Biotechnology Institute Yolk sac stem cells and their uses
AU623922B2 (en) 1988-08-04 1992-05-28 Amrad Operations Pty. Limited In vitro propagation of embryonic stem cells
US5256560A (en) 1988-10-07 1993-10-26 University Of Saskatchewan Primitive cell colony stimulating factors and lymphohematopoietic progenitor cells
US5411883A (en) 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5840580A (en) 1990-05-01 1998-11-24 Becton Dickinson And Company Phenotypic characterization of the hematopoietic stem cell
US5622853A (en) 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
DE69131393T2 (de) 1990-09-10 1999-11-04 Takeda Chemical Industries Ltd Menschlicher Rezeptor für luteinisierendes Hormon und Choriongonadotropin
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US6410320B1 (en) 1992-03-02 2002-06-25 The University Of Michigan Method and compositions for isolation and growth of kidney tubule stem cells, in vitro kidney tubulogenesis and ex vivo construction of renal tubules
CA2109729A1 (en) 1992-03-23 1993-09-30 James G. Bender In vitro-derived human neutrophil precursor cells
WO1994000484A1 (en) 1992-06-22 1994-01-06 Young Henry E Scar inhibitory factor and use thereof
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5690926A (en) 1992-10-08 1997-11-25 Vanderbilt University Pluripotential embryonic cells and methods of making same
SG86980A1 (en) 1992-11-16 2002-03-19 Applied Immunesciences Pluripotential quiescent stem cell population
DE4240635C2 (de) 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren
EP0722331A4 (en) 1993-08-25 1997-10-01 Systemix Inc METHOD FOR PRODUCING A POPULATION OF HIGHLY ENRICHED HEMATOPOIETIC STEM CELLS
US5453457A (en) 1993-11-12 1995-09-26 Bayer Corporation Gamma-radiation-resistant polycarbonate composition
US5972627A (en) 1994-06-15 1999-10-26 Systemix, Inc. Method of purifying a population of cells enriched for dendritic and/or lymphoid progenitors and populations of cells obtained thereby
US5650317A (en) 1994-09-16 1997-07-22 Michigan State University Human breast epithelial cell type with stem cell and luminal epithelial cell characteristics
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5821108A (en) 1995-04-07 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Enrichment for a thymocyte subset having progenitor cell activity using c-kit as a selection marker
US5876956A (en) 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6517872B1 (en) 1995-06-12 2003-02-11 Yeda Research And Development Co., Ltd. FGFR3 as a marker for mesenchymal skeletal progenitor cells
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
GB9514816D0 (en) 1995-07-19 1995-09-20 Ucli Ltd Substances and their medical use
US5858782A (en) 1995-11-13 1999-01-12 Regents Of The University Of Michigan Functional human hematopoietic cells
US5997871A (en) 1996-06-24 1999-12-07 University Of Maryland Biotechnology Insitute Treatment and prevention of cancer by administration of derivatives of human chorionic gonadotropin
US6969608B1 (en) 1996-08-26 2005-11-29 Mcgill University Pharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
US6890724B2 (en) 1996-09-06 2005-05-10 California Institute Of Technology Methods and compositions for neural progenitor cells
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
CA2216439A1 (en) 1996-09-25 1998-03-25 Derek Van Der Kooy Pharmaceuticals containing retinal stem cells
CA2277278A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6583109B1 (en) 1997-06-24 2003-06-24 Robert C. Gallo Therapeutic polypeptides from β-hCG and derivatives
US6734015B1 (en) 1997-07-04 2004-05-11 University Of Utah Research Foundation Isolation of lineage-restricted neuronal precursors
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
CA2307807C (en) 1997-10-23 2008-09-02 Andrea G. Bodnar Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture
AU753975B2 (en) 1997-12-04 2002-10-31 Duke University Methods of isolating and using CD7+CD34-Lin-hematopoietic cells
AU2469299A (en) 1998-01-23 1999-08-09 Cornell Research Foundation Inc. Purified populations of stem cells
AUPP244498A0 (en) 1998-03-18 1998-04-09 Medvet Science Pty. Ltd. Keratinocyte stem cells
US6812027B2 (en) 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
US6835567B1 (en) 1998-04-14 2004-12-28 Signal Pharmaceuticals, Inc. PNS cell lines and methods of use therefor
EP1082410B1 (en) 1998-05-29 2007-08-01 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
US6129911A (en) 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
US6913925B1 (en) 1998-08-12 2005-07-05 Signal Pharmaceuticals Llc Human mesencephalon cell lines and methods of use therefor
DE19837438A1 (de) 1998-08-18 2000-02-24 Biotechnolog Forschung Gmbh Rekombinante Humanzelle für Knochen- und Knorpelzellbildung
US6767737B1 (en) 1998-08-31 2004-07-27 New York University Stem cells bearing an FGF receptor on the cell surface
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
AU2969899A (en) 1998-12-16 2000-07-03 Tsentr Embrionalnykh Tkanei "Emcell" Method for treating patients using cellular suspensions of embryonic tissues
KR20010093280A (ko) 1999-02-24 2001-10-27 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 불임증 치료
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US6551810B1 (en) 1999-04-23 2003-04-22 Ceptyr, Inc. DSP-10 dual-specificity phosphatase
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
AU774876B2 (en) 1999-06-29 2004-07-08 Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
US6761883B2 (en) 1999-06-29 2004-07-13 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
US6872389B1 (en) 1999-07-08 2005-03-29 Rhode Island Hospital Liver stem cell
US6043235A (en) 1999-07-21 2000-03-28 Research Triangle Institute 11β-aryl-17, 17-spirothiolane-substituted steroids
CA2386536A1 (en) * 1999-09-14 2001-03-22 The Children's Medical Center Corporation Methods for treating muscular dystrophy with bone marrow cells
CA2386559A1 (en) 1999-09-14 2001-03-22 The Children's Medical Center Corporation Isolation of muscle-derived stem cells and uses therefor
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
US6753153B2 (en) 1999-12-13 2004-06-22 The Scripps Research Institute Markers for identification and isolation of pancreatic islet α and β progenitors
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
DE60143517D1 (de) * 2000-04-25 2011-01-05 Osiris Therapeutics Inc Wiederherstellung der gelenken mit mesenchymalen stammzellen
NL1017973C2 (nl) 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
US6936281B2 (en) 2001-03-21 2005-08-30 University Of South Florida Human mesenchymal progenitor cell
WO2002018549A1 (en) * 2000-08-30 2002-03-07 Maria Biotech Co., Ltd. Human embryonic stem cells derived from frozen-thawed embryo
US20040071665A1 (en) 2000-09-05 2004-04-15 Yong-Fu Xiao Method for therapeutically treating a clinically recognized form of cardiopathology in a living mammal
US6458588B1 (en) 2001-01-31 2002-10-01 The General Hospital Corporation Renal stem cells and uses thereof
JP2004529621A (ja) 2001-02-14 2004-09-30 ティー ファークト，レオ 多能性成体幹細胞、その起源、それを得る方法および維持する方法、それを分化させる方法、その使用法、ならびにそれ由来の細胞
US6852532B2 (en) 2001-03-21 2005-02-08 University Of Utah Research Foundation Method of isolating human neuroepithelial precursor cells from human fetal tissue
US7202080B2 (en) * 2001-03-29 2007-04-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
US20030017587A1 (en) 2001-07-18 2003-01-23 Rader William C. Embryonic stem cells, clinical applications and methods for expanding in vitro
DE10139783C1 (de) * 2001-08-14 2003-04-17 Transtissue Technologies Gmbh Zellzusammensetzungen zur Behandlung von Osteoarthrose, sowie Verfahren zu deren Herstellung
HUP0501094A2 (en) * 2001-11-06 2006-04-28 Univ Shanghai 2Nd Medical Somatic cell derived embryonic stem cells and its differentiated cells
ATE438708T1 (de) 2001-11-15 2009-08-15 Childrens Medical Center Verfahren zur isolierung, expansion und differenzierung fötaler stammzellen aus chorionzotte, fruchtwasser und plazenta und therapeutische verwendungen davon
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
AU2003225791A1 (en) * 2002-03-15 2003-09-29 Department Of Veterans Affairs, Rehabilitation R And D Service Methods and compositions for directing cells to target organs
US20040009589A1 (en) 2002-03-26 2004-01-15 Shulamit Levenberg Endothelial cells derived from human embryonic stem cells
US7285415B2 (en) * 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
KR20110102961A (ko) 2002-07-25 2011-09-19 더 스크립스 리서치 인스티튜트 조혈 줄기세포 및 이를 사용한 신생혈관 안구 질환의 치료방법
CA2501949A1 (en) * 2002-10-11 2004-04-22 Novocell, Inc. Implantation of encapsulated biological materials for treating diseases
JP2006508076A (ja) 2002-10-11 2006-03-09 リガンド・ファーマシューティカルズ・インコーポレイテッド 選択的プロゲステロン受容体モジュレーター化合物としての５−シクロアルケニル５Ｈ−クロメノ［３，４−ｆ］キノリン誘導体
WO2004033459A1 (en) 2002-10-11 2004-04-22 Ligand Pharmaceuticals Incorporated 5-(1',1'-CYCLOALKYL/ALKENYL)METHYLIDENE 1,2-DIHYDRO-5H-CHROMENO[3,4-f]QUINOLINES AS SELECTIVE PROGESTERONE RECEPTOR MODULATOR COMPOUNDS
US20060252150A1 (en) * 2002-11-08 2006-11-09 Linzhao Cheng Human embryonic stem cell cultures, and compositions and methods for growing same
UA59678A (uk) 2002-11-15 2003-09-15 Національний Медичний Університет Ім. О.О. Богомольця Спосіб лікування ревматоїдного артриту
AU2004219851B2 (en) * 2003-03-12 2009-12-17 Reliance Life Sciences Pvt. Ltd. Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells
CA2536588C (en) 2003-08-29 2018-04-24 Wisconsin Alumni Research Foundation Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
ES2398239T3 (es) 2003-11-10 2013-03-14 The Scripps Research Institute Composiciones y procedimientos para inducir la desdiferenciación celular
US20050106554A1 (en) 2003-11-19 2005-05-19 Palecek Sean P. Cryopreservation of pluripotent stem cells
UA71388A (uk) 2003-12-26 2004-11-15 Інститут Нейрохірургії Імені Академіка А. П. Ромоданова Академії Медичних Наук України Спосіб отримання збагаченої суспензії стовбурових нейральних клітин
US20050233446A1 (en) * 2003-12-31 2005-10-20 Parsons Xuejun H Defined media for stem cell culture
WO2005080551A2 (en) * 2004-02-12 2005-09-01 University Of Newcastle Upon Tyne Stem cells
WO2005099758A2 (en) * 2004-04-17 2005-10-27 The Board Of Trustees The Leland Standford Junior University Injectable bioartificial tissue matrix
WO2006044204A2 (en) 2004-10-05 2006-04-27 University Of Georgia Research Foundation, Inc. Neuronal progenitors from feeder-free human embryonic stem cell culture
EP2422794A3 (en) 2006-03-07 2013-03-13 Geeta Shroff Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation

Also Published As

Publication number Publication date
KR101505382B1 (ko) 2015-03-23
NZ594639A (en) 2013-04-26
EP1993575A2 (en) 2008-11-26
CA2644922A1 (en) 2007-12-13
EP2422796A3 (en) 2013-03-13
US9482660B2 (en) 2016-11-01
CU20080161A7 (es) 2012-11-15
EA200801943A1 (ru) 2009-04-28
AP2949A (en) 2014-07-31
WO2007141657B1 (en) 2008-07-31
US20190369088A1 (en) 2019-12-05
EP2422803A3 (en) 2013-03-13
EP2422799A3 (en) 2013-03-06
US20140057350A1 (en) 2014-02-27
EP2422803A2 (en) 2012-02-29
US20140051164A1 (en) 2014-02-20
US8900861B2 (en) 2014-12-02
EP2422796A2 (en) 2012-02-29
CN103893211A (zh) 2014-07-02
PH12014501028A1 (en) 2016-02-22
US8592208B2 (en) 2013-11-26
BRPI0708576A2 (pt) 2011-05-31
US9488643B2 (en) 2016-11-08
EP2422799A2 (en) 2012-02-29
JP2014159455A (ja) 2014-09-04
AP2008004623A0 (en) 2008-10-31
EP2422802A2 (en) 2012-02-29
EA027648B1 (ru) 2017-08-31
EP2422795A2 (en) 2012-02-29
EP2422800A3 (en) 2013-03-06
AU2007257594A1 (en) 2007-12-13
JP2009528834A (ja) 2009-08-13
ECSP088799A (es) 2008-12-30
EP2422801A3 (en) 2013-03-06
EP2422797A3 (en) 2013-03-20
CN101420964A (zh) 2009-04-29
WO2007141657A3 (en) 2008-04-24
US20090123433A1 (en) 2009-05-14
KR20080106332A (ko) 2008-12-04
US10545135B2 (en) 2020-01-28
GEP20135796B (en) 2013-04-10
EP2422802A3 (en) 2013-03-06
KR20140135263A (ko) 2014-11-25
US9383349B2 (en) 2016-07-05
US20140050706A1 (en) 2014-02-20
MX2008011279A (es) 2008-11-25
EP2422798A2 (en) 2012-02-29
EA027648B9 (ru) 2018-01-31
EP2422795A3 (en) 2013-03-13
AU2007257594B2 (en) 2012-11-01
EP2422798A3 (en) 2013-03-06
NZ571127A (en) 2012-01-12
KR101505202B1 (ko) 2015-03-27
EP2422794A2 (en) 2012-02-29
WO2007141657A2 (en) 2007-12-13
US20130122588A1 (en) 2013-05-16
IL193702A0 (en) 2011-08-01
EP2422800A2 (en) 2012-02-29
EP2422794A3 (en) 2013-03-13
MY154677A (en) 2015-07-15
US20140051110A1 (en) 2014-02-20
US9134299B2 (en) 2015-09-15
CA2644922C (en) 2019-07-23
JP5649786B2 (ja) 2015-01-07
DK1993575T3 (da) 2019-10-14
EP1993575B1 (en) 2019-07-03
US9804151B2 (en) 2017-10-31
MX347303B (es) 2017-04-21
EP2422801A2 (en) 2012-02-29
MA30323B1 (fr) 2009-04-01
EP2422797A2 (en) 2012-02-29
IL193702A (en) 2015-02-26
US20140057250A1 (en) 2014-02-27
NO20084181L (no) 2008-11-26
US20130122486A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
CR10345A (es) Composiciones que comprenden celulas madre embrionarias humanas y sus derivados, metodos de uso y metodos de preparacion
ECSP088152A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
HN2011001195A (es) Compuestos que expanden las celulas madre hematopoieticas
AR047928A1 (es) Derivados de tetrahidropiridoindol
BR112012012529A2 (pt) composto indol e seu uso farmacêutico
UY31952A (es) 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
BR112013031268A2 (pt) "polipeptídeos análogos de pramlintida, uso dos mesmos, composição farmacêutica compreendendo os referidos polipeptídeos e método de preparação da referida composição".
CO6382119A2 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
BR122020001787A8 (pt) Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
BR112014018524A8 (pt) Derivados de pirimido [4,5-b]indol, seus usos, composição farmaceutica, e método in vivo ou ex vivo para aumentar as células estaminais e/ou progenitoras
UY30438A1 (es) Derivados n-sustituidos de 5-halo-4-[2-alquil-1-sustituidos-1h-imidazol-5-il]pirimidin-2-amina, composiciones-procesos para su preparacion y usos
BR112015010908A2 (pt) derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
CL2007002228A1 (es) Composicion farmaceutica topica que comprende 1-(2-metilpropil)-1h-imidazo[4,5-c]quinolin-4-amina; composiicon empacada; metodos para esterelizarlas; util para cicatrizar tejido donde la dermis se ha desgarrado.
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
PA8660301A1 (es) Pirazolo piridinas sustituidas, composiciones que las contienen, procedimiento de fabricacion y utilizacion
UY30762A1 (es) Sal fumarato de (alfa s, beta r)-6-bromo-alfa-[2(dimetilamino) etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
CO6640262A2 (es) Composiciones farmacéuticas y métodos para su elaboración
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
PA8627001A1 (es) Compuestos para el tratamiento de enfermedades
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
WO2015023553A3 (en) Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules
WO2011069037A3 (en) Stabilization and storage of biological pharmaceutical compositions
DE602007002553D1 (de) Ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento

Legal Events

Date Code Title Description
FC Refusal